References
- Rabin KR, Gramatges MM, Margolin JF, Poplack DG. Acute lymphoblastic
leukemia. In– Pizzo PA and Poplack DG, eds. Principles and Practice
of Pediatric Oncology, 7th Edition. Philadelphia,
Wolters Kluwer 2016 pp 463-497.
- Halton J, Gaboury I, Grant R et al. Advanced vertebral fracture among
newly diagnosed children with acute lymphoblastic leukemia: Results of
the Canadian Steroid Associated Osteoporosis in the Pediatric
Population (STOPP) research program. J Bone Miner Res 2009; 24:
1326-1334.
- Halton JM, Atkinson SA, Fraher L et al Mineral homeostasis and bone
mass at diagnosis in children with acute lymphoblastic leukemia. J
Pediatr 1995; 126: 557-564.
- Halton JM, Atkinson SA, Fraher L et al. Altered mineral metabolism and
bone mass in children during treatment for acute lymphoblastic
leukemia. J Bone Miner Res 1996; 11: 1774-1783.
- Sala A, Barr RD. Osteopenia and cancer in children and adolescents.
The fragility of success. Cancer 2007; 109: 1420-1431.
- Barr RD, Sala A. Osteonecrosis in children and adolescents with
cancer. Pediatr Blood Cancer 2008; 50: 483-485.
- Ward LM, Tricco AC, Phoung P et al. Bisphosphonate therapy for
children and adolescents with secondary osteoporosis. Cochrane
Database Syst Rev. 2007: CD 005324.
- Kotecha RS, Powers N, Lee S-J, Murray KJ, Carter T, Cole C. Use of
bisphosphonates for the treatment of osteonecrosis as a complication
of therapy for childhood acute lymphoblastic leukemia (ALL). Pediatr
Blood Cancer 2010; 54: 934-940.
- Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action
and role in clinical practice. Mayo Clin Pract 2008; 83: 1032-1045.
- Barr RD, Guo CY, Wiernikowski J, Webber C, Wright M, Atkinson S.
Osteopenia in children with acute lymphoblastic leukemia: a pilot
study of amelioration with Pamidronate. Med Pediatr Oncol 2002; 39:
44-46.
- Lethaby C, Wiernikowski J, Sala A, Naronha M, Webber C, Barr RD.
Bisphosphonate therapy for reduced bone mineral density during
treatment of acute lymphoblastic leukemia in childhood and
adolescence. A report of preliminary experience. J Pediatr Hematol
Oncol 2007; 29: 613-616.
- Nakhla M, Denker AE, Connor JD et al. Bioavailability and short-term
tolerability of alendronate in glucocorticoid-treated children. Clin
Ther 2011; 33: 1516-1523.
- Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or
stopping Alendronate after 5 years of treatment. The Fracture
Intervention Trial Long-term Extension (FLEX): A randomized trial.
JAMA 2006; 96: 2927-938.
- Tuany Duarte N, de Oliveira Rech B, Godoy Martins I, Bertoldi Franco
J, Lopez Ortega K. Can children be affected by bisphosphonate-related
osteonecrosis of the jaw ? A systematic review. Int J Oral Maxillofac
Surg 2020; 49: 183-191.
- Brown JJ, Ramalingan L, Zacharin MR. Bisphosphonate – associated
osteonecrosis of the jaw: does it occur in children? Clin Endocrinol
(Oxf) 2008; 68: 863-867.
- Sebestyen J, Srivastava T, Alon US. Bisphosphonates use in children.
Clin Pediatr 2012; 51: 1011-1024.
- Mundy GR, Yoneda T. Bisphosphonates as anti-cancer drugs. N Engl J Med
1998; 339: 398-400.
- Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF.
Bisphosphonates for cancer treatment: Mechanisms of action and lessons
from clinical trials. Pharmacol Ther 2016; 158: 24-40.
- Ward LM, Konji VN, Ma J. The management of osteoporosis in children.
Osteoporos Int 2016; 27: 2147-2179.
- Pieters R, Schrappe M, De Lorenzo P et al. A treatment protocol for
infants younger than 1 year with acute lymphoblastic leukemia
(Interfant 99): an observational study and a multi-centre randomized
trial. Lancet 2007; 370: 240-250.
- Vrooman LM, Neuberg DS, Kutok JL et al. Post induction dexamethasone
and individualized dosing of Escherichia coli L-asparaginase each
improve outcome of children and adolescents with acute lymphoblastic
leukemia: results from a randomized study – Dana Farber Cancer
Institute ALL consortium Protocol 00-01. J Clin Oncol 2013:
31:1202-1210.
- Place AE, Stevenson KE, Vrooman LM et al. Intravenous pegylated
asparaginase versus intramuscular native Estherichia coli asparaginase
in newly diagnosed childhood acute lymphoblastic leukemia (DFCI
05-001): a randomized open label phase 3 trial. Lancet Oncol 2015: 16:
1677-1690.
- Silverman L, Blonquist TM, Hunt SK et al. Randomized study of
pegasparaginase (SS-PEG) and calasparagase pegol (SC-PEG) in pediatric
patients with newly diagnosed acute lymphoblastic leukemia or
lymphoblastic lymphoms: results of DFCI ALL Consortium Protocol
11-001. Blood 2016; 128 (22): 175 (abstract).
- Halton JM, Atkinson SA, Fraher L et al. Altered mineral metabolism and
bone mass in children during treatment for acute lymphoblastic
leukemia. J Bone Miner Res 1996; 11: 1774-1783.
- Pierobon J, Webber CE, Nayiager T, Barr RD, Moran GR, Gulenchyn KY.
Radiation doses originating from diagnostic procedures during the
treatment and followup of children and adolescents with malignant
lymphoma. J Radiol Prot 2011; 31: 83-93.
- Sala A, Webber CE, Morrison J, Beaumont LF, Barr RD. Whole-body bone
mineral content, lean body mass, and fat mass measured by dual-energy
x-ray absorptiometry in a population of normal Canadian children and
adolescents. Can Assoc Radiol J 2007; 58:46-52.
- Webber CE, Beaumont LF, Morrison J, Sala A, Barr RD. Age-predicted
values for lumbar spine, proximal femur and whole-body bone mineral
density: Results from a population of normal children aged 3 to 18
years. Can Assoc Radiol J 2007; 58: 37-45.
- Webber CE, Sala A, Barr RD. Accounting for body size deviations when
reporting bone mineral density variables in children. Osteoporos Int
2009; 20: 113-121.
- Zuna J, Cavé H, Eckert C et al. Childhood secondary ALL after ALL
treatment. Leukemia 2006; 21: 1431-1435.
- Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N
Engl J Med 2015; 373: 1541-1552
- Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of
once-weekly oral alendronate on bone in children on glucocorticoid
treatment. Rheumatology 2005; 44: 813-818.
- Nasomyont N, Horning LN, Gordon CM, Wasserman H. Outcomes following
intravenous bisphosphonate infusion in pediatric patients: A 7-year
retrospective chart review. Bone 2019; 121: 60-67.
- Lu J, Shin Y, Yen M-S, Sun SS. Peak bone mass and patterns of change
in total bone mineral density and bone mineral content from childhood
into young adulthood. J Clin Densitom 2016; 19: 180-191.
- Baxter-Jones ADG, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone
mineral accrual from 8 to 30 years of age: An estimation of peak bone
mass. J Bone Miner Res 2011; 26: 1729-1739.
- Heaney RP, Abrams S, Dawson-Hughes B et al. Peak bone mass. Osteoporos
Int 2000; 11: 985-1009.
- Rayar MS, Nayiager T, Webber CE, Barr RD, Athale UH. Predictors of
bony morbidity in children with acute lymphoblastic leukemia. Pediatr
Blood Cancer 2012; 59: 77-82.
- Verwaaijen EJ, de Groot-Kruseman HA, Pieters R et al. Developing and
validating risk prediction models for symptomatic fractures and low
bone mineral density in pediatric acute lymphoblastic leukemia. J Bone
Miner Res 2021, Oct 5. DOI:10.1002/jbmr.4442.
- Fonseca A, Gordon C, Barr RD. Peripheral quantitative computed
tomography (pQCT) to assess bone health in children, adolescents, and
young adults: A review of normative data. J Pediatr Hematol Oncol
2013; 35: 581-589.
- Barr R, Inglis D, Athale U, Farncombe T, Gordon C. Bone health in
long-term survivors of acute lymphoblastic leukemia in childhood an
adolescence. An assessment by peripheral quantitative computed
tomography. Pediatr Blood Cancer 2021; 68: e29218.
- Frost HM. On the trabecular “thickness” – number problem. J Bone
Miner Res 1999; 14: 1816-1821.
- Rizzato G, Montemurro L. Reversibility of exogenous
corticosteroid-induced bone loss. Eur Resp J 1993; 6: 116-119.
- Brennan BM, Mughal Z, Roberts SA et al. Bone mineral density in
childhood survivors of acute lymphoblastic leukemia treated without
cranial irradiation. J Clin Endocrinol Metab 2005; 90: 689-694.
- Mostoufi-Moab S, Brodsky J, Isaacoff EJ et al. Longitudinal assessment
of bone density and structure in childhood survivors of acute
lymphoblastic leukemia without cranial radiation. J Clin Endocrinol
Metab 2012; 97: 3584-3592.
- Golden NH, Iglesias EA, Jacobson MS et al. Alendronate for the
treatment of osteopenia in anorexia nervosa: A randomized,
double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005;
90: 3179-3185.
- Ward LM, Rauch F, Whyte MP et al. Alendronate for the treatment of
pediatric osteogenesis imperfecta: A randomized placebo-controlled
study. J Clin Endocrinol Metab 2011; 96: 355-364.
- Ward L, Tricco AC, Phuong P et al. Bisphosphonate therapy for children
and adolescents with secondary osteoporosis. Cochrane Database Syst
Rev 2007; 4: CD005324.
- Bone HG, Hosking D, Devogelaer J-P, et al. Ten years’ experience with
alendronate for osteoporosis in postmenopausal women. N Engl J Med
2004; 350: 1189-1199.
- Duarte NT, Rech B deO, Martins IS, Franco JB, Ortega KL. Can children
be affaected by bisphosphonate-related osteonecrosis of the jaw ? A
systematic review. Int J Oral Maxillofac Surg 2020; 49: 183-191.
- Clezardin P. Bisphosphonates’ antitumor activity: An unraveled side of
a multifaceted drug class. Bone 2011; 48: 71-79.
- Janke LJ, Kim J, Payton MA et al. Effects of zoledronic acid on
osteonecrosis and acute lymphoblastic leukemia treatment efficacy in
preclinical models. Pediatr Blood Cancer 2021; 68: e29183.
- Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ.
Exposure to oral bisphosphonates and risk of cancer. Int J Cancer
2012; 131: E717-E725.
- Bae YE, Chang J, Park SM. Oral bisphosphonate use and the risk of
female breast, ovarian, and cervical cancer: a nationwide
population-based study. Arch Osteoporos 2019; 14: 41.
- Wen DT, Xu Z, Xuan ML et al. Prognostic effect of bisphosphonate
exposure for patients with diagnosed solid cancer: A systematic review
with meta-analysis of observational studies. Front Oncol 2018: 8: 495.
- Rouach V, Goldshtein I, Wolf I et al. Exposure to alendronate is
associated with a lower risk of bone metastases in osteoporotic women
with early breast cancer. J Bone Oncol 2018; 12: 91-95.
- Rajakumar SA, Papp E, Lee KK et al. B cell acute lymphoblastic
leukemia cells mediate RANK-RANKL – dependent bone destruction. Sci
Transl Med 2020; 12: eaba5942.